In this 30-minute webinar, you will learn about PK Submit, a new add-on to Phoenix WinNonlin that automates the creation of PK CDISC domains during NCA analysis. It can generate both Study Data Tabulation Model (SDTM) and Standard for Exchange of Nonclinical Data (SEND) datasets. PK Submit was designed to create the entire PK regulatory […]
This webinar explored a new version of a 21 CFR Part 11 compliant data repository that significantly improves the clinical pharmacology workflow.
Watch this webinar to learn how to use in vitro and in vivo models to find direct time scaling factors and confirm the similarity of the in vitro and in vivo release mechanisms.
Watch this webinar to learn how RSABE for NTIDs can be performed in Phoenix WinNonlin using a reusable template.
In this webinar, Noreen Muscat from QACV Consulting discussed common pitfalls in validation and how to avoid them, and Allan Michaels, Sr. Project Manager of Phoenix Technology Services, shared how the latest Validation Suite for Phoenix WinNonlin expedites validation and provides robust reporting.
As the gold standard for PK/PD software, our upcoming Phoenix 8.1 release delivers new capabilities to automate processes, reduce errors, and save you time. Dr. Nathan Teuscher, VP of Pharmacometric Consulting, Venkateswari Muthukrishnan, Phoenix WinNonlin Product Manager, and Ana Henry, Executive Director of Training, shared our latest innovations in WinNonlin and NLME and conducted a live demo.
Making Sense of 6MWT Variability: Developing a Disease Progression Model for Duchenne Muscular Dystrophy
Watch this webinar with Drs. Lora Hamuro and Joga Gobburu to learn how they developed a natural history progression model for DMD using the 6MWT.
Watch this webinar to learn how the delay operator implemented in Phoenix 8 can eliminate the need to add complex lines of code for each delay differential equation, simplify modeling delayed outcomes, and avoid inefficient workarounds and approximations.
Watch this webinar with Cen Guo—a graduate student at UNC-Chapel Hill—to learn how she used an integrated approach to predict alterations in bile acid disposition due to inhibition of multiple transporters using the model bile acid taurocholate (TCA).